TREATMENT OF CANCER-PATIENTS WITH ENDOTOXIN INDUCES RELEASE OF ENDOGENOUS CYTOKINES

被引:38
作者
MACKENSEN, A [1 ]
GALANOS, C [1 ]
ENGELHARDT, R [1 ]
机构
[1] MAX PLANCK INST IMMUNBIOL,W-7800 FREIBURG,GERMANY
关键词
LIPOPOLYSACCHARIDE; ENDOGENOUS CYTOKINES; CANCER PATIENTS;
D O I
10.1159/000163659
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
This study sought to determine whether endogenous tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and granulocyte-colony-stimulating factor (G-CSF) were detectable in sera of lipopolysaccharide (LPS)-treated cancer patients. Twenty patients received an intravenous bolus of purified LPS from Salmonella abortus-equi (4.0 ng/kg). Patients were pretreated with ibuprofen (1,600 mg) to prevent constitutional side effects like fever and chills. Serum TNF-alpha levels increased from < 0.01 ng/ml before treatment up to maximal levels of 21 ng/ml, peaking 1.5 h after LPS injection. Similarly, serum IL-6 concentrations increased from < 0.01 to 11 ng/ml, but peak levels were obtained 30 min later than TNF-alpha. Circulating G-CSF appeared still later than TNF-alpha and IL-6. It was detectable within 3 h and peaked 6 h after LPS injection. Parallel to the release of the above cytokines a marked increase in granulocyte counts was observed. In all patients administration of LPS led to an acute-phase response as measured by C-reactive protein.
引用
收藏
页码:264 / 267
页数:4
相关论文
共 13 条
[1]   GROWING TUMORS INDUCE HYPERSENSITIVITY TO ENDOTOXIN AND TUMOR-NECROSIS-FACTOR [J].
BARTHOLEYNS, J ;
FREUDENBERG, M ;
GALANOS, C .
INFECTION AND IMMUNITY, 1987, 55 (09) :2230-2233
[2]  
BOYDEN A, 1974, J IMMUNOL, V57, P211
[3]  
ENGELHARDT R, 1990, J BIOL RESP MODIF, V9, P480
[4]   ELECTRODIALYSIS OF LIPOPOLYSACCHARIDES AND THEIR CONVERSION TO UNIFORM SALT FORMS [J].
GALANOS, C ;
LUDERITZ, O .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1975, 54 (02) :603-610
[5]  
GALANOS C, 1979, ZBL BAKT-INT J MED M, V243, P226
[6]   LYMPHOCYTE HOMING RECEPTORS [J].
GALLATIN, M ;
STJOHN, TP ;
SIEGELMAN, M ;
REICHERT, R ;
BUTCHER, EC ;
WEISSMAN, IL .
CELL, 1986, 44 (05) :673-680
[7]  
JABLONS DM, 1989, J IMMUNOL, V142, P1542
[8]  
KARNOFSKY D, 1961, CLIN PHARMACOL THER, V2, P709
[9]  
MITCHIE HR, 1988, NEW ENGL J MED, V318, P1481
[10]  
POHLMAN TH, 1986, J IMMUNOL, V136, P4548